Multiple primary head and neck squamous cell cancer: Lessons learnt

被引:0
|
作者
Ghogale, Kshitish S. [1 ,2 ]
Naorem, Raphel [1 ,2 ]
Waghmare, Chaitali M. [1 ,2 ]
机构
[1] PIMS DU, Dr Vitthalrao Vikhe Patil Pravara Rural Hosp, Dept Radiat Oncol, Ahmednagar, Maharashtra, India
[2] PIMS DU, Dr Vitthalrao Vikhe Patil Pravara Rural Hosp, Dr Balasaheb Vikhe Patil Rural Med Coll, Ahmednagar, Maharashtra, India
关键词
Field cancerization; head and neck; multiple primary cancer; re-irradiation; squamous cell cancer; 2ND PRIMARY TUMORS; FIELD CANCERIZATION; SINGLE-INSTITUTION; CHANGING PATTERNS; PREVENTION; FAILURE; IMPACT; TRIAL; STAGE;
D O I
10.4103/jcrt.jcrt_392_22
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To analyze the demographic profile, treatment outcome, and factors affecting them in multiple primary head and neck squamous cell cancer (MPHNSCC) patients. Materials and Methods: Hospital case records of patients with histopathology proven MPHNSCC registered in the radiation oncology department from January 2008 to December 2020 were retrospectively studied. Modified Warren-Gates criteria were used to define MPHNSCC. Demographic and clinical details were recorded and analyzed. Results: Twenty-seven patients had histopathology proven MPHNSCC. The median age at diagnosis of an index case was 50 years (minimum 26, maximum 70) with a male to female sex ratio of 22:5. Seventeen (62.96%) patients were tobacco users; either smoked or smokeless. The oral cavity was the commonest sub-site for both an index and second primary malignancy (22 patients; 81.48%) and the majority presented in a locally advanced stage of disease (10; 37.03% and 16; 62.95% for an index and second primary, respectively). The presentation was simultaneous, synchronous, and metachronous in 1 (3.7%), 2 (7.4%), and 24 (88.89%) patients, respectively. Two patients had three sites of MPHNSCC. The average duration of chronicity was 54.37 months (min. 8 and max. 156). MPHNSCC were ipsilateral in 10 (37.04%) patients and re-irradiation was planned for 22 (81.48%) patients with 50% treatment compliance. At the time of the last hospital visit, 18 (66.66%) patients were alive with disease, 7 (25.92%) patients were alive without disease, and 2 (7.40%) patients died of disease. Conclusion: A higher percentage of MPHNSCC originated from the oral cavity and the majority presented in the locally advanced stage of disease; despite the site being accessible to self-oral examination. Patient education and physician's awareness regarding the MPHNSCC are needed.
引用
收藏
页码:S658 / S663
页数:6
相关论文
共 50 条
  • [21] Head and neck squamous cell cancer: Biology (1)
    Mishra A.
    Pandey A.
    Nong X.
    Indian Journal of Otolaryngology and Head & Neck Surgery, 2007, 59 (1) : 28 - 32
  • [22] CHEMOTHERAPY OF SQUAMOUS-CELL CANCER OF THE HEAD AND NECK
    GILL, PG
    HAINS, JD
    IYER, P
    ROZENBILDS, JG
    AHMAD, A
    ABBOTT, RL
    DAVID, DJ
    WARD, GG
    BROWN, MW
    DEANE, N
    HARVEY, M
    MEDICAL JOURNAL OF AUSTRALIA, 1983, 1 (10) : 463 - 466
  • [23] Current Treatment of Head and Neck Squamous Cell Cancer
    Belcher, Ryan
    Hayes, Katherine
    Fedewa, Stacey
    Chen, Amy Y.
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 110 (05) : 551 - 574
  • [24] PRECISION MEDICINE FOR SQUAMOUS CELL CANCER OF THE HEAD AND NECK
    Harrington, Kevin J.
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 7 - 8
  • [25] Pembrolizumab for the treatment of head and neck squamous cell cancer
    Ho, Won Jin
    Mehra, Ranee
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (09) : 879 - 885
  • [26] Development on squamous-cell cancer of the head and neck
    Garcia Saenz, J. A.
    Bueno Muino, C.
    ANALES DE MEDICINA INTERNA, 2008, 25 (04) : 157 - 158
  • [27] EPIDEMIOLOGY OF SQUAMOUS-CELL CANCER OF THE HEAD AND NECK
    CANN, CI
    FRIED, MP
    ROTHMAN, KJ
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 1985, 18 (03) : 367 - 388
  • [28] Prognosis in recurrent head and neck squamous cell cancer
    Baatenburg de Jong, R. J.
    Steyerberg, E.
    van der Schroeff, M.
    ORAL ONCOLOGY, 2007, : 58 - 58
  • [29] Systemic chemotherapy for squamous cell head and neck cancer
    Adelstein, DJ
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (12) : 2151 - 2163
  • [30] Metachronous Second Primary Head and Neck Squamous Cell Carcinoma
    Wu, S. Y.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S316 - S316